- Home
- VYNE
as 03-13-2025 4:00pm EST
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.
| Founded: | 2003 | Country: | United States |
| Employees: | N/A | City: | BRIDGEWATER |
| Market Cap: | 35.7M | IPO Year: | 2018 |
| Target Price: | $6.88 | AVG Volume (30 days): | 71.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.94 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.57 - $4.30 | Next Earning Date: | 03-06-2025 |
| Revenue: | $501,000 | Revenue Growth: | 18.16% |
| Revenue Growth (this year): | -49.1% | Revenue Growth (next year): | 20.00% |
Stock Insider Trading Activity of VYNE Therapeutics Inc. (VYNE)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| LEPORE PATRICK G | VYNE | Director | Jan 15 '25 | Buy | $2.92 | 15,000 | $43,800.00 | 51,472 |
Latest VYNE Therapeutics Inc. News
VYNE Breaking Stock News: Dive into VYNE Ticker-Specific Updates for Smart Investing
Simply Wall St.
7 days ago
VYNE Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag
GlobeNewswire
8 days ago
VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update
GlobeNewswire
22 days ago
VYNE Therapeutics to Participate in March Investor Conferences
GlobeNewswire
23 days ago
VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis
Simply Wall St.
a month ago
3 US Penny Stocks To Watch With Market Caps Over $20M
Argus Research
2 months ago
Daily – Vickers Top Buyers & Sellers for 01/17/2025
GlobeNewswire
2 months ago
VYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluating VYN201 for the Treatment of Nonsegmental Vitiligo
Simply Wall St.
2 months ago
US Penny Stocks To Watch In December 2024
Compare VYNE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VYNE VYNE Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.